FORT, L.P. - CHINA BIOLOGIC PRODS HLDGS I ownership

Quarter-by-quarter ownership
FORT, L.P. ownership history of CHINA BIOLOGIC PRODS HLDGS I
ValueSharesWeighting
Q1 2021$1,191,000
+3.3%
10,055
+3.0%
0.33%
-2.9%
Q4 2020$1,153,000
+34.7%
9,761
+26.7%
0.34%
-4.2%
Q3 2020$856,000
+139.8%
7,703
+120.6%
0.36%
+86.0%
Q2 2020$357,000
-48.9%
3,492
-46.1%
0.19%
+22.9%
Q1 2020$699,000
+219.2%
6,476
+244.8%
0.16%
+302.6%
Q4 2019$219,0001,8780.04%
Other shareholders
CHINA BIOLOGIC PRODS HLDGS I shareholders Q2 2021
NameSharesValueWeighting ↓
Kite Lake Capital Management (UK) LLP 207,382$24,135,00076.46%
Maso Capital Partners Ltd 539,597$62,798,00020.20%
York Capital Management Global Advisors, LLC 1,102,163$128,270,0007.40%
HHLR ADVISORS, LTD. 2,751,200$320,185,0003.99%
Dalton Investments, Inc. 15,551$1,810,0001.14%
Athos Capital Ltd 8,290$965,0000.96%
Myriad Asset Management Ltd. 67,019$7,799,0000.94%
Temasek Holdings (Private) Ltd 990,000$115,216,0000.75%
OXFORD ASSET MANAGEMENT LLP 211,646$24,631,0000.68%
AGF Investments America Inc. 12,230$1,423,0000.47%
View complete list of CHINA BIOLOGIC PRODS HLDGS I shareholders